Plus Therapeutics Inc (PSTV) Stock Price, Quote & News

Company Profile

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat va...

Industry: Biotechnology

Sector: Healthcare

Phone: 737 255 7194

Fax: 210 974 6901

Website: plustherapeutics.com

Address:

6420 LEVIT GREEN BOULEVARD, SUITE 210, Houston, United States

BioHunter1 May. 15 at 5:21 PM

$PSTV Via LinkedIn. https://www.linkedin.com/posts/linkedin-ad126-share-7459573128613187584-c61V?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAAAyTvRcBXRUs03UzwsrhnU54WCXHOHheAKA&utm_campaign=copy_link

0 · Reply

TheVirus0011 May. 15 at 5:15 PM

$PSTV For now, I don't regret selling at $6.50. As I predicted on April 27th, it reached the support level at $5.20 and broke through. Next support is around $4.60. They need to hurry up and release some big news.

2 · Reply

greenday88 May. 15 at 4:19 PM

$PSTV why is it down today?

0 · Reply

Marketmoverjoe May. 15 at 4:16 PM

$PSTV go to 3.00. who cares about this trash

1 · Reply

RookieTrader500 May. 15 at 4:14 PM

$PSTV 3.00 please, thank you

1 · Reply

Marketmoverjoe May. 15 at 4:07 PM

$PSTV drop it to 4.00 already. Just do it. we know that is where we're heading

0 · Reply

Marketmoverjoe May. 15 at 4:02 PM

$PSTV drop some positive news or something.

0 · Reply

andre82 May. 15 at 4:02 PM

$PSTV as long as @Love_To_Learn is commenting you short with both hands! 😂

0 · Reply

BioHunter1 May. 15 at 3:07 PM

$PSTV The SP is detached from reality and makes no sense. Maybe one day we wake up and it’s over $20. GLTAL

1 · Reply

Marketmoverjoe May. 15 at 1:55 PM

$PSTV Really? earnings two wks out. gonna take this down to 3.00. should have sold at 8.00. I know better then to think this company gives too shits about it's holders. all lies

0 · Reply

Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

May 14, 2026, 9:00 AM EDT - 1 day ago

Plus Therapeutics Transcript: AGM 2026

May 8, 2026, 7:30 AM EDT - 7 days ago

Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases

May 7, 2026, 7:30 AM EDT - 8 days ago

Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic

Apr 28, 2026, 7:30 AM EDT - 17 days ago

Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Apr 23, 2026, 7:30 AM EDT - 22 days ago

Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™

Apr 22, 2026, 4:30 PM EDT - 22 days ago

Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

2026-04-21T11:59:57.000Z - 24 days ago

Plus Therapeutics regains compliance with Nasdaq minimum bid price requirement

Apr 21, 2026, 7:30 AM EDT - 24 days ago

Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Apr 15, 2026, 7:30 AM EDT - 4 weeks ago

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

2026-04-09T11:57:58.000Z - 5 weeks ago

Plus Therapeutics appoints Eric Daniels as chief development officer

Apr 9, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Appoints Eric J. Daniels, M.D.

2026-04-08T11:39:50.000Z - 5 weeks ago

Plus Therapeutics granted Orphan Drug Designation for Reyobiq

Apr 8, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas

2026-04-07T15:15:27.000Z - 5 weeks ago

Plus Therapeutics price target lowered to $12 from $37.50 at Maxim

2026-04-07T11:55:34.000Z - 5 weeks ago

Plus CNSide Cerebrospinal Fluid Tumor Cell Enumeration test gets AMA PLA code

Apr 7, 2026, 7:30 AM EDT - 5 weeks ago

Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption

2026-04-06T22:20:10.000Z - 5 weeks ago

Plus Therapeutics’ treatment of malignant glioma granted FDA orphan designation

Apr 2, 2026, 7:30 AM EDT - 6 weeks ago

Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives

2026-04-01T23:50:16.000Z - 6 weeks ago

Plus Therapeutics Inc (USA) trading halted, news pending

2026-03-31T14:45:55.000Z - 6 weeks ago

Plus Therapeutics downgraded to Hold from Buy at D. Boral Capital

2026-03-31T11:38:10.000Z - 6 weeks ago

Plus Therapeutics announces 1-for-25 reverse stock split

Mar 26, 2026, 7:30 AM EDT - 7 weeks ago

Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors

2026-03-19T12:01:47.000Z - 2 months ago

Plus Therapeutics’ CNSide assay may reduce healthcare costs

Mar 19, 2026, 7:30 AM EDT - 2 months ago

Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%

2026-03-12T21:05:16.000Z - 2 months ago

Plus Therapeutics reports Q4 EPS (29c), consensus (4c)

Mar 12, 2026, 4:15 PM EDT - 2 months ago

Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout

2026-02-25T12:39:49.000Z - 2 months ago

Plus announces new Category III CPT code for CED used with Reyobiq

Feb 25, 2026, 7:30 AM EST - 2 months ago

Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™

2026-02-03T13:40:32.000Z - 3 months ago

Plus Therapeutics initiated with a Buy at Lake Street

2026-01-23T15:00:32.000Z - 4 months ago

Plus Therapeutics price target lowered to $1.50 from $3 at Maxim

2026-01-23T11:11:22.000Z - 4 months ago

Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright

Jan 22, 2026, 9:00 AM EST - 4 months ago

Plus Therapeutics Transcript: Business update

2026-01-22T12:50:20.000Z - 4 months ago

Plus Therapeutics announces anticipated milestones for FY26

Jan 21, 2026, 4:15 PM EST - 4 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

2026-01-14T13:17:53.000Z - 4 months ago

Plus Therapeutics prices 39.5M units at 38c in upsized public offering

Jan 14, 2026, 8:00 AM EST - 4 months ago

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

2026-01-09T21:15:15.000Z - 4 months ago

Plus Therapeutics files to sell 22.32M units

2026-01-08T12:36:17.000Z - 4 months ago

Plus announces completion of Type B meeting with U.S. FDA for REYOBIQ

Jan 8, 2026, 7:30 AM EST - 4 months ago

Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases

2025-12-11T12:40:58.000Z - 5 months ago

Plus Therapeutics expands CNSide assay platform to State of California

Dec 11, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Expands CNSide Assay Platform to State of California

Dec 9, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants

Dec 4, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics Highlights Three REYOBIQ™ Clinical Data Presentations at 2025 WFNOS/SNO Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Plus Therapeutics to Present ReSPECT Phase 1 Dose Escalation Study Results for Leptomeningeal Metastases at the 2025 San Antonio Breast Cancer Symposium

Nov 24, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Announces Completion of U.S. FDA Meeting on Future Clinical Development Plans for REYOBIQ™ in Leptomeningeal Metastases

Nov 20, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Secures National Coverage Agreement with Humana for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Nov 17, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement

Nov 6, 2025, 7:30 AM EST - 6 months ago

Plus Therapeutics Highlights ReSPECT-LM Clinical Trial Results at 40th SITC Annual Meeting, Melanoma Research Foundation Brain Metastases Summit 4.0

Oct 30, 2025, 4:15 PM EDT - 7 months ago

Plus Therapeutics Reports Third Quarter Financial Results and Recent Business Highlights

Oct 21, 2025, 7:30 AM EDT - 7 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Sep 25, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

Sep 22, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT

Sep 18, 2025, 7:30 AM EDT - 8 months ago

Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory

Sep 2, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria

Aug 18, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases

Aug 15, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Reports Stockholders' Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements

Aug 14, 2025, 4:15 PM EDT - 9 months ago

Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights

Aug 14, 2025, 7:30 AM EDT - 9 months ago

Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference

Jul 31, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic

Jul 23, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT

Jul 15, 2025, 7:30 AM EDT - 10 months ago

Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases

Jul 10, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference

Jul 8, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 30, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

Jun 26, 2025, 9:00 AM EDT - 11 months ago

Plus Therapeutics Transcript: Business Update

Jun 26, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary

Jun 25, 2025, 4:15 PM EDT - 11 months ago

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET

Jun 25, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Jun 24, 2025, 7:30 AM EDT - 11 months ago

Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing

May 30, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights

May 23, 2025, 4:15 PM EDT - 1 year ago

Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q

BioHunter1 May. 15 at 5:21 PM

0 · Reply

TheVirus0011 May. 15 at 5:15 PM

2 · Reply

greenday88 May. 15 at 4:19 PM

$PSTV why is it down today?

0 · Reply

Marketmoverjoe May. 15 at 4:16 PM

$PSTV go to 3.00. who cares about this trash

1 · Reply

RookieTrader500 May. 15 at 4:14 PM

$PSTV 3.00 please, thank you

1 · Reply

Marketmoverjoe May. 15 at 4:07 PM

$PSTV drop it to 4.00 already. Just do it. we know that is where we're heading

0 · Reply

Marketmoverjoe May. 15 at 4:02 PM

$PSTV drop some positive news or something.

0 · Reply

andre82 May. 15 at 4:02 PM

$PSTV as long as @Love_To_Learn is commenting you short with both hands! 😂

0 · Reply

BioHunter1 May. 15 at 3:07 PM

$PSTV The SP is detached from reality and makes no sense. Maybe one day we wake up and it’s over $20. GLTAL

1 · Reply

Marketmoverjoe May. 15 at 1:55 PM

$PSTV Really? earnings two wks out. gonna take this down to 3.00. should have sold at 8.00. I know better then to think this company gives too shits about it's holders. all lies

0 · Reply

andre82 May. 15 at 1:58 AM

$PSTV lmao 50 is now 2 dollars post split. What a tool. Trying to bait new fish to short, let it die back to 3 dollars already and stfu. Everyday more useless bs spewing on this page

0 · Reply

Vulnerable May. 14 at 10:37 PM

$PSTV The last time Mo posted something almost identical to this the price dropped 50% from .66 ($16.50) to .33 ($8.25), and down some more.

1 · Reply

Love_To_Learn May. 14 at 9:45 PM

$PSTV bypassing retail order books cockroaches

0 · Reply

Love_To_Learn May. 14 at 8:40 PM

$PSTV ALL SHORTS ON THIS STOCK U HAVE BEEN PLACED MORE THAN ON NOTICE COMING 4 U !

2 · Reply

Love_To_Learn May. 14 at 8:39 PM

$PSTV BROUGHT U A SNACK BELOVED B4 I DESTROY SHORTS ! $PIII

0 · Reply

Love_To_Learn May. 14 at 8:35 PM

$PSTV ALL SHORT INTEREST IS NOW CHANGED ON U * IN PREPARATION FOR THE COCKROACHES

0 · Reply

Love_To_Learn May. 14 at 8:35 PM

$PSTV $SLS SECURING FLOORS ! I

1 · Reply

Love_To_Learn May. 14 at 8:28 PM

$PSTV SEE U WHEN I DESTROY U COCKROACHES !

0 · Reply

Love_To_Learn May. 14 at 8:26 PM

$PSTV LOCKING DOWN 30.31 33.33 34.34 38.14 39.6 29.21 REDISTRIBUTING INSTITUTIONAL SHARES ACROSS THE 20-39 RANGE FLEXING HER GATE THE GATE BELONGS TO HER 11.10 (11.12) 11.11 CODING

0 · Reply

Love_To_Learn May. 14 at 8:25 PM

$PSTV JUST 4 U SO U DONT THINK IM BLUFFING SHIFTING OUR ABOVE 50 PT CHANNEL!

1 · Reply

Love_To_Learn May. 14 at 8:18 PM

$PSTV I WILL PRAY FOR U WHEN I DO THIS * SHORTS

0 · Reply

Love_To_Learn May. 14 at 8:18 PM

$PSTV I DONT WANT TO HURT U BUT U LEAVE ME NO CHOICE SHORTS !

0 · Reply

Market Cap	39.11M
Revenue (ttm)	5.21M
Net Income (ttm)	-22.39M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-429.75%
Debt to Equity Ratio	0.19

Volume	163,068
Avg Vol	346,647
Day's Range	N/A - N/A
Shares Out	6.86M
Stochastic %K	34%
Beta	1.40
Analysts	Sell
Price Target	$38.50